Now medicines for these four serious diseases will be available cheaply, know the new rate

[ad_1]

About 6 to 8 percent of the population in India has chronic disease, which means 84 million to 100 million Indians are living with conditions for which treatments either do not exist or are prohibitively expensive. In such a situation, Indian pharmaceutical companies have reduced the prices of medicines for serious diseases. It is estimated that the medicine is likely to be available in early 2024. Apart from critical illnesses, the government has also urged the industry to produce an oral solution for hydroxyurea, needed to treat children up to 5 years of age suffering from sickle cell disease.

which diseases

• tyrosinemia type 1

• gaucher disease

• Wilson’s disease

• and Dravet-Lennox-Gastaut syndrome

medicine to treat gaucher disease

Gaucher disease, a condition that causes fat to accumulate in the liver, spleen, and bones. Due to which the risk of fracture increases. The price of Eliglustat capsules, used for its treatment, has come down from Rs 1.8 crore to Rs 3.6 crore for an adult to Rs 3 lakh to Rs 6 lakh per year.

Price of medicine for Wilson’s disease

Wilson’s disease is a disease where excessive accumulation of copper occurs in the cornea, liver, and brain, causing psychiatric symptoms. The price of Trientine capsules used for its treatment has reduced from Rs 2.2 crore to Rs 2.2 lakh for a 10 kg child.

How much will it take to cure tyrosinemia type 1?

Tyrosinemia type 1 A metabolic condition where the body cannot break down amino acids due to a missing enzyme, causing them to accumulate in the liver and cause severe liver disease. Imported Nitisinone capsules are used for its treatment. Whose annual cost was approximately Rs 2.2 crore. This has been reduced to about Rs 2.5 lakh per year by Indian companies.

lennox-gastaut syndrome medicine price

The lowest price drop is ninefold for cannabidiol oral solution, which is used to treat Dravet and Lennox-Gastaut syndromes – genetic epilepsy syndromes – for which the imported drug costs about $7 per year for a 10-kg child. Rs lakh to Rs 34 lakh. Whereas the price of Indian made medicine ranges from around Rs 1 lakh to Rs 5 lakh. The companies also agreed to produce these drugs without profit. These medicines cannot be profitable because very few people need them.

Capsules or tablets for hydroxyurea are easily available in the market, but the solution is not available. The price of the oral suspension is around US$840 or Rs 70,000 for a 100 ml bottle. A senior health ministry official has said that Akmes Drugs has already applied for approval from the drug regulator and is likely to hit the market from March 2024. Its price will be around Rs 405 per bottle.

[ad_2]

Source link